Peptide T TFA
Names
[ CAS No. ]:
1610056-01-3
[ Name ]:
Peptide T TFA
Biological Activity
[Description]:
Peptide T (TFA) is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a ligand for the CD4 receptor and prevents binding of HIV to the CD4 receptor.
[Related Catalog]:
[Target]
CD4, HIV[1]
[In Vitro]
Peptide T acts to block viral entry as it inhibits in the MAGI cell assay and blocks infection in the luciferase reporter assay using HIV virions pseudotyped with ADA envelope. Peptide T selectively inhibits HIV replication using chemokine receptor CCR5 compared to CXC4[2]. Peptide T at 10-8 M induces IL-10 production by the human Th2 cell line and PBMC. Also peptide T at 10-9 M concentration significantly inhibits IFN-g production by PBMC[3].
[In Vivo]
Peptide T is administered subcutaneously at different doses and phases of the experimental autoimmune encephalomyelitis (EAE) disease, but Peptide T neither prevents nor ameliorates EAE[4].
[Cell Assay]
Peripheral blood mononuclear cells are stimulated with PHA (5 mg/mL) along with various concentrations of peptide T (10-6-10-12 M) for 48 h at 37°C. Supernatants are collected and frozen until analysis[3].
[Animal admin]
Rats[4] Peptide T (125, 250, 500, 800 μg) is randomly given subcutaneously to Female Lewis rats aged 6-8 weeks in the hind foot flanks in a final volume of 0.2 mL. Control animals receive the same volume of saline alone[4].
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Molecular Formula ]:
C37H56F3N9O18
[ Molecular Weight ]:
971.89
[ Storage condition ]:
2-8℃